PGI34 TREATMENT SATISFACTION WITH MEDICATIONS FOR GASTROESOPHAGEAL REFLUX DISEASE: RESULTS FROM A LARGE DISEASE REGISTRY
Bharmal M 1 , Cascade E 2 , Thiny M 3 1 Quintiles, Falls Church, VA, USA, 2 iGuard, Falls Church, VA, USA, 3 Quintiles, Morrisville, NC, USA OBJECTIVES: To assess patient satisfaction with proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs), which are widely used to treat gastroesophageal reflux disease (GERD), among a community-based population in the US. METHODS: Patients are recruited for this ongoing disease registry from multiple sources including physician, pharmacy and online referrals to a medication monitoring service (www. iGuard.org). A random sample of patients reporting using PPIs and H2RAs were invited to complete the Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM), a 14-item reliable and valid instrument to assess patients' satisfaction with medication, providing scores on four scales-Effectiveness, Side Effects, Convenience and Global Satisfaction. Analyses were conducted to evaluate differences in patient satisfaction across GERD medication class (PPIs vs. H2RAs) and individual medications within each class using analysis of covariance models. RESULTS: Data from a total of 1896 patients, 1629 on PPIs and 267 on H2RAs were analyzed for this study. Among PPIs, 498 patients were on esomeprazole, 199 on lansoprazole, 690 on omeprazole, 160 on pantoprazole and 82 on rabeprazole. Among H2RAs, 24 patients were on cimetidine, 63 on famotidine and 180 on ranitidine. After adjusting for patient age, gender, self-reported severity and number of concomitant medications, patients on PPIs had significantly higher scores on Effectiveness (p < 0.0001), Convenience (p = 0.0007) and Global Satisfaction (p = 0.0003) as compared to H2RAs. After controlling for multiple comparisons, no significant differences were observed in TSQM scale scores for individual H2RA medications, however some significant differences were observed within PPIs. For example, patients on esomeprazole (p < 0.0001), pantoprazole (p = 0.0391) and rabeprazole (p = 0.0021) had a significantly higher score on Convenience compared to patients on omeprazole. CONCLUSIONS: This large observational study found significant differences in treatment satisfaction with different GERD treatment classes and individual medications. This real-world feedback from patients can assist clinicians in making treatment decisions.
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PGI35 PROTON PUMP INHIBITOR USE IN SENIORS: AN ANALYSIS FOCUSING ON DRUG CLAIMS 2001 TO 2008
Hunt J, Gaucher M Canadian Institute for Health Information, Ottawa, ON, Canada OBJECTIVES: Acid-related diseases of the gastrointestinal system affect an estimated 29% of Canadian adults. Two drug classes, proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are commonly used to prevent and treat these conditions. PPIs have shown improved efficacy over H2RAs, and are generally considered to be safe medications with few adverse effects. However, there have been increasing concerns regarding adverse effects associated with long-term and high-dose PPI use. METHODS: Claims level data from the National Prescription Drug Utilization Information System (NPDUIS) Database were analyzed for seniors on public drug programs in 6 Canadian provinces between 2001-2002 and 2006-2007 . This analysis compares PPI use to that of H2RAs and breaks down use by age and sex. The analysis also explores the influence PPI dosages and length of therapy may be having on the overall trend in PPI use. RESULTS: The age-sex standardized rate of PPI use among seniors on public drug programs increased from 13.1% in 2001-2002, to 21.1% in 2007-2008 . During the same time period, H2RA use fell from 12.7% to 8.8%. The average daily dose of PPIs used by seniors on public drug programs remained relatively stable, with roughly 80% of PPI claimants using an average daily dose within the standard dosage range each year. The rate of chronic PPI use increased, with 65.8% of seniors taking PPIs considered to be chronic users in 2007-2008. CONCLUSIONS: There was a significant increase in the use of PPIs among seniors on public drug programs in Canada, which coincided with a decrease in H2RA use. Although the average daily dose of PPIs used by these seniors did not increase during the study period, a higher proportion of seniors were taking PPIs for longer periods of time.
PGI36 USING PROPENSITY SCORE MATCHING TO ESTIMATE DIFFERENCES IN HEALTH CARE UTILIZATION BETWEEN PEOPLE WITH AND WITHOUT ULCERATIVE COLITIS
Thanh NX, Ohinmaa A, Jacobs P Institute of Health Economics, Edmonton, AB, Canada OBJECTIVES: To estimate the average difference in health care utilization between people with and without ulcerative colitis (UC) in Canada. METHODS: Using the 2007-2008 Canadian Community Health Survey data, we applied a single-difference propensity score matching approach to estimate the average differences in the number of inpatient days, the number of family physician/general practitioner (GP) consultations, and the number of specialist (Sp) consultations per person per year in 12-yearor-older population with and without UC. Variables included in a stepwise logistic regression with the sampling weight to estimate the propensity scores for matching were socio-demographic characteristics, perceived health, other chronic conditions, and health related behaviours. We used a bootstrap method to estimate the 95% confidence intervals of the differences. We also used a balance test to estimate the bias before and after matching. RESULTS: Using the sampling weight, the UC prevalence rate in Canada was estimated at 0.46%. The average number per person per year of inpatient days was 1.396 and 0.868, of GP consultations was 5.006 and 3.553, and of Sp consultations was 1.538 and 0.903, for people with and without UC, respectively. The average differences between people with and without UC in inpatient days, GP consultations, and Sp consultations were 0.528 (95%CI: 0.013-1.042), 1.453 (95%CI: 0.598-2.308), and 0.635 (95%CI: 0.345-0.925), respectively. The balance test showed that the mean of bias was dramatically reduced after matching (from 21.0 to 1.7). CONCLUSIONS: People with UC used significantly more health care resources than those without the disease. Results of this study can be used to provide background information from the UC patients for evaluations of UC treatments and interventions.
PGI37 FACTORS ASSOCIATED WITH THE USE OF ENTERAL AND PARENTERAL PROTON PUMP INHIBITOR USE IN CRITICALLY ILL PATIENTS
Sankaranarayanan J, Olsen KM, Reardon T, Hays EM, Orwe LA University of Nebraska Medical Center, Omaha, NE, USA OBJECTIVES: Despite the potential advantages of enteral route, parenteral proton pump inhibitors (PPIs) are routinely ordered in the Intensive Care Unit (ICU) for stress ulcer prophylaxis (SUP). Therefore, we studied patient characteristics associated with enteral vs. parenteral PPI use in critically ill patients needing acid-suppression for SUP. METHODS: A retrospective study of electronic medical record data of ≥ 19 year-old adult patients admitted to a Midwest Academic Medical Center's ICU was undertaken. Patients that received a PPI from January 2007 through December 2008 were included. Patient data {age, gender, nonoperative/postoperative status, number of underlying illnesses, any oral medication use, oro-gastric tube, nothing by oral route (NPO), resource utilization variables (hospital days, ICU days) and PPI-use (enteral/ parenteral)} were extracted. Statistical differences between enteral and parenteral PPI patient groups by each of the patient factors and resource utilization variables was determined using Chi-square or fisher's exact test and Wilcoxon-rank-sum tests. The association of specific patient characteristics (any oral medication use, oro-gastric tube, NPO) with enteral versus parenteral PPI-use was tested in univariate logistic regression analyses. RESULTS: Of 148 patients, 50% received enteral PPIs and 50% received parenteral PPIs. The enteral and parental PPI groups did not differ by mean age (60.2 versus 57.1 years, P > 0.05), male/female gender (52.7%/47.3% versus 62.2%/37.8%, p > 0.50), nonoperative/postoperative patient-status (58.7%/41.3% versus 51.8%/48.3%, p > 0.05) or mean number of underlying illnesses (5.3 versus 5.5, P > 0.05). The enteral and parental PPI groups differed significantly by median hospital days (7.0 versus 11.0, p = 0.0018), and median ICU days (2.0 versus 3.0 p = 0.0325). In logistic regression analyses, any oral medication use, oro-gastric tube and NPO were not associated with enteral versus parenteral PPI-use (P > 0.05). CONCLUSIONS: Decisions on the use of parenteral versus enteral PPI need to consider individual patient characteristics. To promote informed formulary decisionmaking and cost-effective quality of care more research is needed.
